卡培他滨联合多西他赛对晚期乳腺癌患者肿瘤标志物水平的影响

摘要

目的 探究卡培他滨联合多西他赛对晚期乳腺癌患者肿瘤标志物水平的影响.方法 随机选取于2010年12月至2015年12月该院收治的75例晚期乳腺癌患者作为研究对象,根据入院时间先后将患者分成观察组38例和对照组37例,对照组患者采用多西他赛治疗,观察组患者采用卡培他滨联合多西他赛治疗,观察并比较两组患者临床疗效、治疗前后血清癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原15-3(CA15-3)水平变化以及毒副反应发生情况.结果 观察组患者接受治疗后,有效率(RR)为63.16%(24/38),疾病控制率(DCR)为86.84%(33/38);对照组RR为40.54%(15/37),DCR为67.57%(25/37),两组比较差异有统计学意义(P<0.05).两组患者治疗前血清中肿瘤标志物CEA、CA125及CA15-3水平比较差异无统计学意义(P>0.05);治疗后,两组CEA、CA125及CA15-3水平较治疗前有明显降低,且差异有统计学意义(P<0.05);治疗后观察组3种肿瘤标志物水平显著低于对照组,且差异有统计学意义(P<0.05).结论 卡培他滨联合多西他赛治疗晚期乳腺癌患者后血清内肿瘤标志物水平显著降低,毒副作用轻,患者耐受性好,值得广泛推荐使用于临床当中.%Objective To explore the effects of combination of capecitabine and docetaxel for the treatment on advanced breast cancer and their influence on tumor biomarkers.Methods The 75 cases with advanced breast cancer were randomly recruited from December 2010 to December 2015 in our hospital,and they were divided into the observation group (38 cases) and control group (37 cases) according to the admission time,the patients in control group were treated with docetaxel,while patients in the observation group were treated with combination of capecitabine and docetaxel,the clinical efficacy before and after treatment was observed,and the changes of serum CEA,glucose CA125,CA15-3 and adverse reaction were compared between two groups.Results The effective rate (RR) of the control group was 40.54% (15/37),and the disease control rate (DCR) was 67.57% (25/37).The RR was 63.16% (24/38) and DCR was 86.84% (33/38)in the observation group.There was significant difference between the two groups (P<0.05).No statistically significant difference was observed between the two groups on the the levels of serum tumor biomarker,CEA,CA125 and CA15-3 before treatment (P>0.05);After treatment,the levels of CEA,CA125 and CA15-3 in both two groups were significantly lower than those before treatment (P<0.05);Moreover,after treatment,the observation group of three tumor biomarkers were significantly lower than those of the control group (P<0.05).Conclusion Combination of capecitabine and docetaxel in the treatment of advanced breast cancer can reduce the serum tumor biomarkers significantly,attenuate the side effects,and the patients are in the good tolerance,it can be widely recommended in clinical use.